#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Longer survival without liver transplant in patients with PBC treated with OCA?

Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
Source: Primary Biliary Cholangitis 20. 3. 2023

News From Biomarker Testing to NSCLC Treatment Selection

During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof. Martin Reck from the Department of Thoracic Oncology at the hospital in Grosshansdorf, Germany, discussed precision medicine in the treatment of non-small cell lung cancer (NSCLC). We have selected an overview of advancements in next-generation sequencing from his presentation for you.
Source: Non-Small Cell Lung Cancer 23. 5. 2022

News Recurring allergy symptoms after waking up? It could be due to dust mites

Allergens that are part of the feces and exoskeleton of dust mites, invisible members of human households, can cause milder symptoms like mucosal swelling, itching of the nose or throat, but also a stronger immune reaction, asthma, or severe allergic rhinitis. It is stated that 1−2% of the global population suffers from dust mite allergy, which corresponds to 65−130 million people. Why does it arise and what can be done in its prevention and treatment?
Source: Dust Mite Allergy 19. 1. 2022

News Vaccination Against COVID-19 in Patients Treated With Anticoagulants

Canadian professional societies and the National Health Service (NHS) in the United Kingdom recommend COVID-19 vaccination even for patients treated with anticoagulants. The benefit of vaccination in these patients significantly outweighs the risk of hematoma associated with intramuscular injection. The recommendation applies to both warfarin and direct oral anticoagulants (DOACs).
Source: Anticoagulant Treatment 11. 10. 2021

News Alzheimer's Disease – Another Pandemic on the Horizon?

Due to the COVID-19 pandemic, other current problems often get pushed into the background. One of these is the aging population and the increasing prevalence of dementia. The key question thus becomes how to extend the period of active aging as much as possible.
Source: Cognitive in the treatment of Alzheimer's disease 11. 2. 2022

News Dual therapy improves not only lung function but also quality of life in COPD patients

Chronic obstructive pulmonary disease (COPD) reduces the quality of life of patients and is one of the main causes of morbidity and mortality. According to international recommendations, the initial pharmacotherapy is recommended as monotherapy with LAMA (long-acting muscarinic antagonists) or LABA (long-acting beta-agonists), or their combination. A pooled analysis of 4 studies compared the early addition of LABA to LAMA in patients with moderate to severe COPD.
Source: COPD 15. 4. 2021

News Chairwoman of Revma Liga ČR: I Hope We Improve Our Approach and Treatment of Osteoporosis in the Czech Republic

Patients with inflammatory rheumatic diseases have a significantly increased risk of developing osteoporosis and related fractures. At the same time, this disease is considerably underestimated in the Czech Republic, and more attention is given to it only at the stage of osteoporotic fractures. To what extent does the patient organization Revma Liga ČR, which unites patients with rheumatic diseases, engage in this issue? We asked its chairwoman Edita Müllerová.
Source: Osteoporosis – Trends in Sequential Therapy 20. 12. 2023

Journal articles Proton radiation therapy in the treatment of solid tumours

Author of the article: J. Kubeš, V. Vondráček, J. Abrahámová Source: Praktický lékař | 1/2019 28. 12. 2018

News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight

Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.
Source: Thromboprophylaxis 3. 3. 2022

News Romiplostim Before Splenectomy in a Patient with ITP - Case Report

In the following case report from authors at a university hospital in Barcelona, the successful use of romiplostim as a second-line treatment before planned splenectomy in a patient with immune thrombocytopenia (ITP), liver cirrhosis, and iatrogenic Cushing's syndrome is demonstrated.
Source: Immune Thrombocytopenia 25. 11. 2022

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.
Source: Oncological Treatment 22. 11. 2021

News Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke

A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.
Source: Pain Management 13. 5. 2024

News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS

Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.
Source: Modulation of S1P in the Treatment of Autoimmune Diseases 28. 8. 2023

News Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?

An article by French authors published in January this year in the journal Multiple Sclerosis and Related Disorders evaluated the effect of teriflunomide on fatigue in patients with multiple sclerosis in real-world practice.
Source: Multiple Sclerosis 19. 4. 2021

News Teriflunomide and Pregnancy Planning

The authors of the article published last year in Multiple Sclerosis Journal present data regarding experiences with the use of teriflunomide during pregnancy.
Source: Multiple Sclerosis 25. 3. 2021

News Bone density in hemophiliacs − known and less-known risk factors

Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?
Source: Hemophilia 20. 8. 2022

News Eletriptan as an effective and safe drug in acute migraine therapy

In the pharmacotherapy of acute migraine attacks, a pharmacologically diverse group of triptans is particularly used. The choice of the right antimigraine drug should be individualized, based on the intersection of the patient's nature of complaints and the pharmacological profile of the drug. The following text briefly summarizes the basic characteristics and profile of eletriptan.
Source: Treatment of Severe Migraine 20. 9. 2021

News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia

Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
Source: Hemophilia 1. 11. 2021

News Von Willebrand Disease as a Cause of Abnormal Uterine Bleeding

Abnormal uterine bleeding constitutes a large portion of complaints among women of reproductive age. This type of bleeding is typical for von Willebrand disease (vWD), but also for other types of coagulation disorders. So, is vWD more frequent in women with abnormal uterine bleeding than in the general population?
Source: Von Willebrand Disease 16. 7. 2021

News Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism

Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75 µg), creating obstacles for some patients to achieve an optimal maintenance dose. The availability of tablets that allow for dosing in between these values facilitates precise and effective titration of levothyroxine doses, especially at the lower end of the spectrum.
Source: Thyroid Disorders 23. 2. 2024

News Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment

With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS – point-of-care ultrasound – has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint bleeding are also being investigated, though their routine use is not anticipated in the near future.
Source: Hemophilia 10. 6. 2024

News Traveling with MS – Is Vaccination a Limitation?

What about the need for vaccination when traveling abroad? Which vaccines should you be cautious about? And how to time vaccination concerning disease activity and the individual medications used in multiple sclerosis (MS) therapy?
Source: Multiple Sclerosis 5. 6. 2023

News Efficacy of L. reuteri DSM 17938 in the Treatment of Infantile Colic

Infantile colic represents a syndrome of behavioral disorders in infants characterized by episodes of uncontrollable crying, wailing, and restlessness without an identifiable cause. This is a common health issue affecting an estimated 5–40% of infants. There are no uniform criteria for the treatment of this benign condition yet, but available studies show a beneficial effect from administering probiotics containing Limosilactobacillus reuteri (previously known as Lactobacillus reuteri) compared with placebo and other treatment methods.
Source: GI, colic and microbiome 30. 3. 2022

News Intestinal Gel LECIG in the Treatment of Advanced Parkinson's Disease in Real Practice

A recently published study presents the first experiences with an intestinal gel containing a triple combination of antiparkinsonian drugs and dosed via an infusion pump through percutaneous endoscopic gastrostomy extended into the jejunum in the treatment of advanced Parkinson's disease.
Source: Parkinson's Disease 10. 3. 2023

News Position of Enoxaparin and DOACs in Extended Prevention of VTE After Surgeries for Gynecological Malignancies

The prophylaxis of venous thromboembolism is a crucial part of postoperative management in oncological diseases, including gynecological malignancies. A newly published survey study conducted in Australia and New Zealand focused precisely on these. The authors were interested in different types of postoperative prophylactic regimens and the potential use of direct oral anticoagulants (DOACs) in them.
Source: Thromboprophylaxis 3. 1. 2024

1 21 22 23 24 25 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#